Published in Biochim Biophys Acta on August 04, 2010
Photochemical mechanisms of light-triggered release from nanocarriers. Adv Drug Deliv Rev (2012) 1.40
Light-activated content release from liposomes. Theranostics (2012) 1.06
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv (2013) 1.06
Photoresponsive nanoparticles for drug delivery. Nano Today (2015) 0.89
Polymeric lipid assemblies as novel theranostic tools. Acc Chem Res (2011) 0.89
Phototriggerable liposomes: current research and future perspectives. Pharmaceutics (2013) 0.86
Photodegradable polyesters for triggered release. Int J Mol Sci (2012) 0.78
Quantitative analysis of phospholipids using nanostructured laser desorption ionization targets. Lipids (2011) 0.78
Photo activation of HPPH encapsulated in "Pocket" liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts. Int J Nanomedicine (2014) 0.77
Low-visibility light-intensity laser-triggered release of entrapped calcein from 1,2-bis (tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine liposomes is mediated through a type I photoactivation pathway. Int J Nanomedicine (2013) 0.77
Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2017) 0.77
Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma (2012) 0.76
Mechanisms of Light-induced Liposome Permeabilization. Bioeng Transl Med (2016) 0.75
Physicochemical characterizations of functional hybrid liposomal nanocarriers formed using photo-sensitive lipids. Sci Rep (2017) 0.75
Gazelles, unicorns, and dragons battle cancer through the Nanotechnology Startup Challenge. Cancer Nanotechnol (2016) 0.75
The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid. J Biol Chem (1960) 21.21
Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov (2005) 10.97
Shedding light onto live molecular targets. Nat Med (2003) 8.47
Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet (2003) 3.58
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta (1993) 2.92
Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta (1991) 2.08
Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res (2005) 1.86
Cytosolic drug delivery using pH- and light-sensitive liposomes. Adv Drug Deliv Rev (1999) 1.52
Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res (2001) 1.48
Light-sensitive intelligent drug delivery systems. Photochem Photobiol (2009) 1.42
The depth of porphyrin in a membrane and the membrane's physical properties affect the photosensitizing efficiency. Biophys J (2002) 1.27
Liposome clearance. Biosci Rep (2002) 1.25
Phototriggering of liposomal drug delivery systems. Adv Drug Deliv Rev (2001) 1.25
Quantitative measurement of fusion of HIV-1 and SIV with cultured cells using photosensitized labeling. Virology (2002) 1.12
HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res (2008) 1.05
DESIGN OF LIPOSOMES CONTAINING PHOTOPOLYMERIZABLE PHOSPHOLIPIDS FOR TRIGGERED RELEASE OF CONTENTS. J Therm Anal Calorim (2009) 1.04
Wavelength-programmed solute release from photosensitive liposomes. Biochem Biophys Res Commun (2000) 1.00
Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum. FEBS Lett (1980) 1.00
Vascular-targeted molecular imaging using functionalized polymerized vesicles. J Magn Reson Imaging (2002) 0.98
Polymerized phosphatidyl choline vesicles. Stabilized and controllable time-release carriers. Biochem Biophys Res Commun (1981) 0.98
Combined effects of laser-ICG photothermotherapy and doxorubicin chemotherapy on ovarian cancer cells. J Photochem Photobiol B (2009) 0.97
Elongated supramolecular assemblies in drug delivery. J Control Release (2002) 0.94
Characterization of diacetylenic liposomes as carriers for oral vaccines. Chem Phys Lipids (2003) 0.93
Structure of polymerizable lipid bilayers. I--1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine, a tubule-forming phosphatidylcholine. Chem Phys Lipids (1988) 0.92
Design of photocleavable lipids and their application in liposomal "uncorking". Chem Commun (Camb) (2005) 0.91
An efficient synthesis of phosphatidylcholines. J Lipid Res (1990) 0.91
Plasma-induced release of solutes from small unilamellar liposomes is associated with pore formation in the bilayers. Biochem J (1981) 0.90
Interactions of liposomes with cells in vitro and in vivo: opsonins and receptors. Curr Drug Metab (2001) 0.87
Liposome/DNA systems: correlation between association, hydrophobicity and cell viability. Biotechnol Lett (2007) 0.86
Active uptake of drugs into photosensitive liposomes and rapid release on UV photolysis. Photochem Photobiol (2000) 0.85
Implications of the generation of reactive oxygen species by photoactivated calcein for mitochondrial studies. Eur J Biochem (2000) 0.85
Fast solute release from photosensitive liposomes: an alternative to 'caged' reagents for use in biological systems. FEBS Lett (1995) 0.85
Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. Exp Mol Pathol (2010) 0.84
Visible light-induced destabilization of endocytosed liposomes. FEBS Lett (2000) 0.84
Chiral tubule self-assembly from an achiral diynoic lipid. Proc Natl Acad Sci U S A (2003) 0.81
Temperature-sensitivity of liposomal lipid bilayers mixed with poly(N-isopropylacrylamide-co-acrylic acid). J Biochem (1997) 0.80
Photodynamic enhancement of doxorubicin cytotoxicity. Cancer Chemother Pharmacol (1994) 0.78
Mechanism of action and spectrum of cell types susceptible to doxorubicin photochemotherapy. Cancer Chemother Pharmacol (1997) 0.77
[Use of liposomes for drug targeting]. Ukr Biokhim Zh (1978) (1984) 0.77
Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen. Oncology (Williston Park) (1999) 0.76
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A (2002) 4.48
The HIV Env-mediated fusion reaction. Biochim Biophys Acta (2003) 3.37
Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol (2005) 1.76
Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol (2005) 1.75
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst (2009) 1.73
Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J Virol (2002) 1.64
Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem (2006) 1.54
Structure and dynamics of micelle-associated human immunodeficiency virus gp41 fusion domain. Biochemistry (2005) 1.52
Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry (2007) 1.46
Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol (2008) 1.41
Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review). Mol Membr Biol (2003) 1.30
Ceramide, a target for antiretroviral therapy. Proc Natl Acad Sci U S A (2004) 1.22
Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry (2005) 1.20
Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J Infect Dis (2007) 1.13
Quantitative measurement of fusion of HIV-1 and SIV with cultured cells using photosensitized labeling. Virology (2002) 1.12
The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J Mol Biol (2004) 1.10
Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J Biol Chem (2006) 1.09
Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection. Bioconjug Chem (2009) 1.08
Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. Biochemistry (2003) 1.07
Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. J Biol Chem (2007) 1.06
Sphingomyelinase restricts the lateral diffusion of CD4 and inhibits human immunodeficiency virus fusion. J Virol (2007) 1.06
HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res (2008) 1.05
Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. J Virol (2008) 1.05
DESIGN OF LIPOSOMES CONTAINING PHOTOPOLYMERIZABLE PHOSPHOLIPIDS FOR TRIGGERED RELEASE OF CONTENTS. J Therm Anal Calorim (2009) 1.04
Anticancer β-hairpin peptides: membrane-induced folding triggers activity. J Am Chem Soc (2012) 1.03
Progressive truncations C terminal to the membrane-spanning domain of simian immunodeficiency virus Env reduce fusogenicity and increase concentration dependence of Env for fusion. J Virol (2003) 1.03
Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. J Virol (2005) 1.01
C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion. J Biol Chem (2003) 0.99
HIV-1 gp41 transmembrane domain interacts with the fusion peptide: implication in lipid mixing and inhibition of virus-cell fusion. Biochemistry (2012) 0.99
Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide. Biochem Biophys Res Commun (2007) 0.99
Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. Retrovirology (2006) 0.98
Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother (2009) 0.98
HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. J Leukoc Biol (2005) 0.97
Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41. Biochemistry (2004) 0.96
Light-sensitive lipid-based nanoparticles for drug delivery: design principles and future considerations for biological applications. Mol Membr Biol (2010) 0.96
Sphingolipids: modulators of HIV-1 infection and pathogenesis. Biosci Rep (2005) 0.96
Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). J Control Release (2011) 0.96
Functional reconstitution of protein ion channels into planar polymerizable phospholipid membranes. Nano Lett (2005) 0.95
Photoinduced reactivity of the HIV-1 envelope glycoprotein with a membrane-embedded probe reveals insertion of portions of the HIV-1 Gp41 cytoplasmic tail into the viral membrane. Biochemistry (2008) 0.95
An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T-cells. AIDS (2004) 0.93
Acid-induced changes in thermal stability and fusion activity of influenza hemagglutinin. Biochemistry (2002) 0.93
A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. AIDS (2006) 0.93
The C- and the N-terminal regions of glycoprotein 41 ectodomain fuse membranes enriched and not enriched with cholesterol, respectively. J Biol Chem (2004) 0.92
The role of glycosphingolipids in HIV signaling, entry and pathogenesis. Glycoconj J (2004) 0.92
Fluorescent lipid probes in the study of viral membrane fusion. Chem Phys Lipids (2002) 0.92
Sphingolipids, cholesterol, and HIV-1: a paradigm in viral fusion. Glycoconj J (2006) 0.91
HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development. Vaccine (2008) 0.91
Mechanism of membrane permeation induced by synthetic β-hairpin peptides. Biophys J (2013) 0.90
Polymeric lipid assemblies as novel theranostic tools. Acc Chem Res (2011) 0.89
Fusion of HIV-1 envelope-expressing cells to human glomerular endothelial cells through an CXCR4-mediated mechanism. Pediatr Nephrol (2005) 0.88
Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents. Antimicrob Agents Chemother (2011) 0.88
Fenretinide inhibits HIV infection by promoting viral endocytosis. Antiviral Res (2005) 0.88
Functional expression of CD4, CXCR4, and CCR5 in glycosphingolipid-deficient mouse melanoma GM95 cells and susceptibility to HIV-1 envelope glycoprotein-triggered membrane fusion. Virology (2004) 0.87
Synthesis of pyridines by carbenoid-mediated ring opening of 2H-azirines. Angew Chem Int Ed Engl (2013) 0.87
Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41. FASEB J (2011) 0.86
Elevated expression of GM3 in receptor-bearing targets confers resistance to human immunodeficiency virus type 1 fusion. J Virol (2004) 0.86
Restricted lateral mobility of plasma membrane CD4 impairs HIV-1 envelope glycoprotein mediated fusion. Mol Membr Biol (2008) 0.86
Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. FASEB J (2010) 0.86
Activation of different split functionalities on re-association of RNA-DNA hybrids. Nat Nanotechnol (2013) 0.86
The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion. Virol J (2006) 0.85
Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. Exp Mol Pathol (2010) 0.84
Altered bystander apoptosis induction and pathogenesis of enfuvirtide-resistant HIV type 1 Env mutants. AIDS Res Hum Retroviruses (2009) 0.84
A covalent inhibitor targeting an intermediate conformation of the fusogenic subunit of the HIV-1 envelope complex. J Biol Chem (2007) 0.84
Characterization of the effects of aryl-azido compounds and UVA irradiation on the viral proteins and infectivity of human immunodeficiency virus type 1. Photochem Photobiol (2010) 0.84
Multiple site-specific in vitro labeling of single-chain antibody. Bioconjug Chem (2009) 0.83
Co-transcriptional production of RNA-DNA hybrids for simultaneous release of multiple split functionalities. Nucleic Acids Res (2013) 0.81
Mapping the Vif-A3G interaction using peptide arrays: a basis for anti-HIV lead peptides. Bioorg Med Chem (2013) 0.81
Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1. Virology (2010) 0.81
Material properties of matrix lipids determine the conformation and intermolecular reactivity of diacetylenic phosphatidylcholine in the lipid bilayer. Langmuir (2011) 0.81
Effects of UVA irradiation, aryl azides, and reactive oxygen species on the orthogonal inactivation of the human immunodeficiency virus (HIV-1). Virology (2011) 0.80
Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry. Antiviral Res (2008) 0.80
Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy. Curr Top Med Chem (2011) 0.80
Improved separation of integral membrane proteins by continuous elution electrophoresis with simultaneous detergent exchange: application to the purification of the fusion protein of the human immunodeficiency virus type 1. Electrophoresis (2002) 0.79
Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a DL-amino acid-containing fusion peptide: possible recognition of the fusion complex. J Biol Chem (2004) 0.79
Lipids in viral fusion. Methods Mol Biol (2002) 0.79
Ectopic ATP synthase facilitates transfer of HIV-1 from antigen-presenting cells to CD4(+) target cells. Blood (2012) 0.79